Sign Up to like & get
recommendations!
1
Published in 2021 at "Hepatology"
DOI: 10.1002/hep.32094
Abstract: Despite being one of the common diseases, the treatment options for nonalcoholic steatohepatitis (NASH) are still limited. Recently, Gawrieh et al. demonstrated significant improvement in liver enzymes and liver fat content (LFC) in nonalcoholic fatty…
read more here.
Keywords:
saroglitazar treatment;
treatment;
editor saroglitazar;
nafld nash ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Current vascular pharmacology"
DOI: 10.2174/1570161115666170621082910
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease (30% of the general population) and up to 40% of cases advance to the more severe form of the disease: nonalcoholic steatohepatitis (NASH), which…
read more here.
Keywords:
use;
treatment;
disease;
statin ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Metabolites"
DOI: 10.3390/metabo12030238
Abstract: Non-alcoholic fatty liver (NAFLD) over the past years has become a metabolic pandemic linked to a collection of metabolic diseases. The nuclear receptors ERRs, REV-ERBs, RORs, FXR, PPARs, and LXR are master regulators of metabolism…
read more here.
Keywords:
nuclear receptors;
treatment nafld;
receptors treatment;
emerging role ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2019 at "Nutrients"
DOI: 10.3390/nu11071578
Abstract: Non-alcoholic fatty liver disease (NAFLD) is caused by the imbalance between lipid deposition and lipid removal from the liver, and its global prevalence continues to increase dramatically. NAFLD encompasses a spectrum of pathological conditions including…
read more here.
Keywords:
potential use;
use metabolic;
treatment;
metabolic cofactors ... See more keywords